A study involving almost 14,000 cancer patients has linked increased survival rates with regular aspirin use. The research involved sufferers of various forms of gastrointestinal tumors and found that patients who starting to use aspirin after they had been diagnosed doubled their chances of survival.
Different patients with the same type of cancer can have different
responses to the same medication, which leaves doctors in a tough spot:
how do they know which treatment will have the best response? If they
get it right, their patient may enter remission; but if they're wrong
the patient's health will deteriorate. Now researchers at Western
University might have the answer. They developed machine learning
algorithms – a branch of artificial intelligence – that crunch genetic
data to determine the most likely treatment response and allow more
personalized treatment regimens.
With a lack of clear symptoms even when the disease is well progressed, more than 80 percent of pancreatic cancer diagnoses come after the cancer has already spread. This has led some researchers to look beyond blood to urine testing, which is a less complex fluid. Among those is a team at the Queen Mary University of London, which has uncovered a three-protein biomarker in the urine of pancreatic cancer sufferers, suggesting a less invasive, early stage test may be on the way.
As with every form of the deadly disease, early detection of oesophageal cancer is critical to recovery. The current approach of detecting the cancer through biopsy can be a little hit and miss, so the University of Cambridge's Professor Rebecca Fitzgerald and her team have developed what they claim to be a more accurate tool for early-diagnosis. Billed as "a pill on a string," the Cytosponge is designed to scrape off cells from the length of the oesophagus as it is yanked out after swallowing, offering up a much larger sample for inspection of cancer cells.
Building on previous work, researchers at Duke University have developed a new technology that wraps nanoshells in a thin film of drug-infused hydrogel, adding additional firepower to the already promising targeted cancer treatment. The hydrogel is loaded with cancer-fighting drugs and coated onto the nanoshells, which heat up when exposed to infrared light and release the chemotherapeutic drugs, delivering a one-two punch, directly to the tumour.
When things in our body go awry, through disease or infection, for example, the types of molecules in our breath can change. These variations have presented researchers around the world with a very real opportunity to detect various conditions, including lung cancer, with unprecedented ease. The latest scientists to start sniffing around this emerging form of medical diagnosis is a team from the University of Adelaide, who are developing a laser instrument inspired by dog's nose that can screen breath samples for signs of unrest.
Future cancer treatments may target your genes rather than the cancerous cells themselves. A new study found that reactivating a single gene was enough to stop and reverse colorectal cancer (that's cancer of the colon, or bowels) in mice, with a return to normal intestinal functions within just four days and tumors gone within two weeks. The concept, though not the specific method, could lead to new treatments of a variety of cancers.
A new study has pointed to a chink in the armor of skin cancer cells, suggesting that they can be overpowered by the body's own system with help from a pioneering approach known as viral therapy. A clinical trial has demonstrated that a genetically engineered herpes virus can not only plant itself in the cancer cells and kill them off, but activate the body's own immune system to stave off harmful tumors.
A drug long-used to counter the negative effects of chemotherapy has won US Food and Drug Administration (FDA) approval for use in treating the nasty effects of exposure to radiation following a nuclear disaster. Known commercially as Neupogen, the drug has been shown to work by shielding the body's white blood cells to heighten a patient's chances of survival.